Abstract

Warfarin oral anticoagulant is most prescribed in the world. Warfarin is prescribed for prevention of thromboembolic event, associated with atrial fibrillation, prosthetic heart valves, or history of vascular thrombosis. Variability in warfarin dose because of the variation among the patient and therapeutic response depend on age, influence of another disease, nutritional status, weight, concomitant medicine, influence of genetic polymorphism of the CYP2C9 or VKORC1. Optimal dose warfarin can be monitored with international normalized ratio (INR). The aims of this study is to compare initial warfarin response between obese and non obese patient at RSUP dr. Sardjito Yogyakarta. This study was a retrospective with design descriptive observational study. Subject in research is outpatient that receive newly warfarin therapy and with complete INR value. To determine time required to achieve a therapeutic INR was analyzed using non parametric test with Kaplan-Meier method. The result of this study, 92 patient were included. Patient distribution were 44 patient with obesity and 48 patient with normal weight. Based on Kaplan-Meier analyzed the median time to achieve therapeutic INR in obese patient is 56 days and in normal weight is 57 days with p=0,316 (p>0,05) there is no significant difference between the group. Key word: Warfarin, Obese, non obese, INR, time to achieve therapeutic INR

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call